Mission Statement, Vision, & Core Values (2026) of Pacific Shuanglin Bio-pharmacy Co., LTD.

At the heart of Pacific Shuanglin Bio-pharmacy Co., Ltd. lies a bold commitment to breakthrough biopharmaceuticals and patient-centered care: Pacific Shuanglin Bio-pharmacy Co., Ltd. channels substantial resources into R&D-allocating roughly 15% of annual revenue in 2022-to advance antibiotics, cardiovascular therapies and other critical products, translating a robust product portfolio into global reach where 60% of sales come from international markets; in 2023 the company reported revenue of ¥5 billion and is targeting growth of 20% annually over the next five years while upholding core values of innovation, integrity, cooperation, tolerance and responsibility to ensure regulatory rigor, strategic partnerships and a continually evolving pipeline of life‑saving treatments.

Pacific Shuanglin Bio-pharmacy Co., LTD (000403.SZ) - Intro

• Therapeutic focus: antibiotics, cardiovascular, metabolic and select specialty biologics.
• Business model: integrated R&D → GMP manufacturing → national & international distribution.
• Distribution reach: nationwide hospital and retail channels plus export markets in Asia and select global partners.

• Develop safe, effective and accessible medicines that improve patient outcomes.
• Drive biotechnology innovation to transform clinical practice and public health.
• Operate with transparency, compliance and quality across the value chain.

• Become a globally respected biopharma innovator recognized for breakthrough therapies and manufacturing excellence.
• Position China as a hub for cost-effective, high-quality biopharmaceutical products.

• Scientific rigor - evidence-driven development and continuous improvement.
• Patient-centricity - safety, accessibility and therapeutic value guide decisions.
• Integrity - regulatory compliance, ethical conduct and quality assurance.
• Collaboration - strategic partnerships, open innovation and talent development.

• R&D intensity: allocated approximately 15% of 2022 annual revenue to research and development.
• Focus: lifecycle improvements for existing products, next-generation antibiotics and cardiovascular therapies, and selective biologics programs.
• Infrastructure: in-house labs, clinical trial capabilities and GMP production lines supporting scale-up.

• Collaborations with academic institutions and CROs to accelerate preclinical and clinical programs.
• Distribution network partnerships enabling hospital tender access and retail pharmacy distribution across China.
• Selective export agreements to expand presence in regional markets.

Pacific Shuanglin Bio-pharmacy Co., LTD (000403.SZ) - Overview

• Develop high-quality pharmaceutical products that improve the quality of life for patients worldwide.
• Emphasize innovation, patient-centric solutions, and sustainability across operations.
• Leverage cutting-edge biotechnology and extensive research to deliver effective therapies and measurable healthcare improvements.
• Advance public health through sustained R&D investment, clinical collaboration, and strict regulatory compliance.

• Become a globally recognized biopharmaceutical innovator delivering accessible, safe, and effective therapies.
• Scale solutions that translate laboratory breakthroughs into scalable clinical benefits and improved patient outcomes.
• Establish sustainable manufacturing and distribution practices that reduce environmental impact while expanding market access.

• Integrity - transparent governance, ethical clinical practices, and compliance with regulatory standards.
• Collaboration - cross-disciplinary partnerships with clinicians, academic institutions, and industry peers.
• Excellence - rigorous quality control, evidence-driven R&D, and continuous improvement across functions.
• Patient-first orientation - design and prioritize programs that deliver tangible benefits to patients and caregivers.

• R&D investment strategy: sustained allocation that prioritized pipeline advancement and translational research (15% of revenue in 2022).
• Clinical partnerships: coordinated trials and clinician engagement to accelerate evidence generation and regulatory filings.
• Sustainability practices: integration of environmental and social governance into procurement and manufacturing decisions.

• R&D spend as % of revenue (trend vs. 15% baseline in 2022).
• Number of clinical programs entering Phase I/II/III annually.
• Regulatory submissions and approvals per year.
• Commercial launch success rates and post-market safety metrics.

Pacific Shuanglin Bio-pharmacy Co., LTD (000403.SZ) - Mission Statement

• Advance breakthrough biologics and small‑molecule therapies with a focus on oncology, autoimmune disorders, and metabolic diseases.
• Drive patient‑centric solutions through precision medicine, personalized dosing strategies, and improved access to therapies.
• Invest in scalable manufacturing and global distribution to ensure affordability and availability in key markets.
• Maintain strong corporate governance, ethical clinical practices, and partnerships with academic and industry leaders.

• R&D leadership: scale up translational research, biologics pipelines, and clinical trial capacity.
• Global footprint: deepen presence in North America, Europe, and emerging APAC markets, leveraging partners and distributors.
• Commercial excellence: expand product portfolio while optimizing pricing and reimbursement strategies.
• Patient focus: incorporate real‑world evidence and patient‑reported outcomes into development and post‑market programs.

• Personalized therapies and biomarker‑driven trials to increase responder rates and accelerate regulatory approvals.
• Enhanced access programs and tiered pricing in lower‑income markets to broaden patient reach.
• Post‑market surveillance and real‑world data integration to optimize long‑term outcomes and safety.

• Expand manufacturing capacity and CMO partnerships to support biologics scale‑up and reduce time‑to‑market.
• Forge global licensing and co‑development agreements to accelerate entry into North American and European markets.
• Increase digital health integration for remote monitoring, adherence programs, and patient support services.

Pacific Shuanglin Bio-pharmacy Co., LTD (000403.SZ) - Vision Statement

• Innovation: continuous investment in drug discovery, formulation and process optimization to accelerate time-to-market for high-value medicines.
• Integrity: transparent governance, regulatory compliance and delivering on commitments to patients, providers and investors.
• Cooperation: strategic alliances with academic institutions, contract research/ manufacturing organizations and international distributors to scale impact.
• Tolerance: inclusive corporate culture that values diverse perspectives and constructive debate to drive better solutions.
• Responsibility: environmental stewardship, pharmacovigilance and patient safety embedded across operations.

• Integrity in contracts and regulatory filings - timely disclosure and quality-first release criteria.
• Innovation pipelines prioritized by unmet medical need and commercial viability, with rigorous stage-gate governance.
• Cooperative partnerships - licensing, co-development and CMO agreements to broaden therapeutic reach.
• Responsibility initiatives - pharmacovigilance systems, workplace safety programs and environmental controls in production.
• Team culture - incentive structures, continuous training and cross-functional project teams to foster passion and possibility-oriented mindset.

• Patients: expand access through affordable pricing strategies and broadened distribution channels.
• Healthcare partners: deliver consistent supply reliability and co-development opportunities.
• Investors: pursue balanced growth-targeting steady revenue growth with disciplined R&D ROI and margin improvement.
• Regulators & communities: maintain transparent reporting and adherence to environmental and safety standards.